After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.
| Inventor | Institute |
|---|---|
| Walter Bodmer | Cancer Research UK, London Research Institute: Lincoln's Inn Fields |
| Cat. #: | 153253 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Biochemistry;Cell biology;Immunology;Neurobiology |
| Application: | Fn ; IP |
| Target: | Human complement component 3 |
| Reactivity: | Human |
| Clone: | WM1 |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. |
|---|---|
| Conjugation: | Unconjugated |
| Isotype: | IgG1 lambda |
| Immunogen: | Human complement component 3 |
| Myeloma used: | P3X63Ag8 |
| Target background: | C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes. |
|---|
| Format: | Liquid |
|---|---|
| Shipping conditions: | Dry ice |
| References: |
Whitehead et al. 1981. Eur J Immunol. 11(2):140-6. PMID: 6163641. A monoclonal antibody against human complement component C3: the production of C3 by human cells in vitro. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151019 | Anti-Mos [S3.1] |
Key Info
Anti-Mos [S3.1]
|
View Tool | |||||||||||||||||||
| 151024 | Anti-Hairy [1/24] |
Key Info
Anti-Hairy [1/24]
|
View Tool | |||||||||||||||||||
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
| 151029 | Anti-HSVICP8 [11E2] |
Key Info
Anti-HSVICP8 [11E2]
|
View Tool | |||||||||||||||||||
| 151040 | Anti-CD11 & CD18 [24] |
Key Info
Anti-CD11 & CD18 [24]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.